New shingles pain drug shows promise in early trial
NCT ID NCT01106716
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This study tested a single dose of an experimental drug called KAI-1678 in 23 adults with long-term nerve pain from shingles (postherpetic neuralgia). The goal was to see if it could reduce pain within 6 hours compared to a placebo or an active painkiller. The trial is complete, but results are not yet widely reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTHERPETIC NEURALGIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Sydney, New South Wales, Australia
Conditions
Explore the condition pages connected to this study.